A Phase 2 interventional study of Luvadaxistat and Placebo in Schizophrenia, sponsored by Neurocrine Biosciences. Completed at 54 sites in 8 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-02-28.
Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Schizophrenia by Neurocrine Biosciences — 6 open to participants now, 6 under way, 4 of them phase 3. Schizophrenia · Neurocrine Biosciences.
Among the 16 studies in Schizophrenia by Neurocrine Biosciences, this one is the 6th largest by enrollment, is one of 2 that started in 2018, is one of 6 in phase 2, and was the 5th registered.
3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.
Browse Schizophrenia studies →6 of the 16 studies in Schizophrenia by Neurocrine Biosciences are open now, in 7 countries. Recruiting first, the newest first:
Neurocrine Biosciences · Sites in Bulgaria, Romania, United Kingdom
Ages 18–55
Neurocrine Biosciences · Sites in United States, Puerto Rico, Serbia
Ages 18–65
Neurocrine Biosciences · Sites in United States
Ages 18+
Neurocrine Biosciences · Sites in United States, Bulgaria, Hungary and 2 more countries
Ages 18–65
Neurocrine Biosciences · Sites in United States, Bulgaria, Puerto Rico and 2 more countries
Ages 18–65
By country, each count listing its studies:
Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2018.
This study's enrollment of 256 is above the median of 70 across 2,953 interventional studies indexed under Schizophrenia.
Median enrollment 165 across the 16 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Neurocrine Biosciences is the lead sponsor of 88 studies on the registry; 18 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.
3 of the studies in Schizophrenia by Neurocrine Biosciences that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06963034Phase 3Neurocrine BiosciencesNBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | 2027-10 |
| NCT07105098Phase 3Neurocrine BiosciencesNBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | 2027-11 |
| NCT07288333Neurocrine BiosciencesEvaluation of NBI-1117570 in Inpatient Adults With Schizophrenia | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies in Schizophrenia by Neurocrine Biosciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether add-on luvadaxistat is superior to placebo on the Positive and Negative Syndrome Scale Negative Symptom Factor Score (PANSS NSFS).
The drug being tested in this study is called luvadaxistat. Luvadaxistat is being tested to treat negative symptoms in participants who have schizophrenia.
Participants will be randomly assigned (by chance, like flipping a coin) to one of the four treatment groups in the double-blind period-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received luvadaxistat 50 mg orally once daily (QD) for 12 weeks (Days 1 to 84).
Drug: Luvadaxistat
Participants received luvadaxistat 125 mg orally QD for 12 weeks (Days 1 to 84).
Drug: Luvadaxistat
Participants received luvadaxistat 500 mg orally QD for 12 weeks (Days 1 to 84).
Drug: Luvadaxistat
Participants received placebo (matching luvadaxistat) orally QD for 12 weeks (Days 1 to 84).
Drug: Placebo
TAK-831 tablets.
Also known as: TAK-831, NBI-1065844
Luvadaxistat placebo-matching tablets.
Change From Baseline on the PANSS NSFS at Week 12
PANSS assesses the positive symptoms, negative symptoms and general psychopathology associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Here, the PANSS NSFS subscale consists of 7 items which assess the negative symptoms with subscale score ranging from 7 to 49, where a higher score indicates greater severity. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as least squares (LS) mean change from baseline at Week 12, determined using a mixed model for repeated measures (MMRM). A negative change from baseline indicates improvement.
Time frame: Baseline and Week 12
Change From Baseline on the PANSS NSFS at Week 4 and Week 8
PANSS assesses the positive symptoms, negative symptoms and general psychopathology associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Here, the PANSS NSFS subscale consists of 7 items which assess the negative symptoms with subscale score ranging from 7 to 49, where a higher score indicates greater severity. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Weeks 4 and 8, determined using a MMRM. A negative change from baseline indicates improvement.
Time frame: Baseline and Weeks 4 and 8
Change From Baseline on the Brief Negative Symptom Scale (BNSS) Total Score (12-item) at Week 12
The BNSS is a 13-item instrument that measures 5 domains of negative symptoms: blunted affect, alogia, asociality, anhedonia and avolition. All items in the BNSS are rated on a 7-point (0-6) scale, with anchor points generally ranging from symptoms being absent (0) to severe (6). Here, the BNSS total score (12-item, excluding item 4) was calculated by summing the 12 individual items; total score range of 0 to 72, where a higher score indicates higher severity of negative symptoms. Participants required a BNSS total score ≥28 to be eligible for the study (excluding item 4). Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Week 12, determined using a MMRM. A negative change from baseline indicates improvement.
Time frame: Baseline and Week 12
Change From Baseline on the Brief Assessment of Cognition in Schizophrenia (BACS) Composite Score at Week 12
BACS is a cognition assessment battery and includes brief assessments of reasoning and problem solving, verbal fluency, attention, verbal memory, working memory and motor speed. The primary measure from each test is standardized by creating T-scores whereby the mean of the test session of a healthy person is set to 50 and the standard deviation set to 10. A composite T-score is calculated by averaging the 6 standardized primary measures. The composite T-score indicates how much higher or lower the participants cognition is compared to a healthy person. Lower T-scores are indicative of lower cognitive performance. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Day 12, determined using a MMRM.
Time frame: Baseline and Week 12
Change From Baseline on the Clinical Global Impression-Schizophrenia Severity (CGI-SCH-S) Negative Symptoms Score at Week 12
The CGI-SCH scale is an adapted version of the CGI scale that is designed to assess global illness status in participants with schizophrenia. CGI-SCH-S is a 7-point scale that requires the investigator to rate the severity of the participant's illness at the time of assessment. Here, CGI-SCH-S negative symptoms score assesses the severity of illness for negative symptoms on the following 7-point scale: 1. normal, not at all ill; 2. borderline mentally ill; 3. mildly ill; 4. moderately ill; 5. markedly ill; 6. severely ill; or 7. among the most extremely ill. Baseline was defined as the last observed value before the first dose of study treatment. The number of participants with each CGI-SCH-S negative symptoms score at baseline and at Week 12 is reported.
Time frame: Baseline and Week 12
Clinical Global Impression Schizophrenia Improvement (CGI-SCH-I) Negative Symptoms Score at Week 12
The CGI-SCH-I assesses the participant's improvement (or worsening). CGI-SCH-I requires the investigator to assess the participant's condition relative to baseline on a 7-point scale. Here, CGI-SCH-I negative symptoms score assesses the improvement for negative symptoms on the following scale: very much improved; 2. much improved; 3. minimally improved; 4. no change; 5. minimally worse; 6. much worse; or 7. very much worse. Baseline was defined as the last observed value before the first dose of study treatment. The number of participants with each CGI-SCH-I negative symptoms score at Week 12 is reported.
Time frame: Baseline up to Week 12
Change From Baseline on the Schizophrenia Cognition Rating Scale (SCoRS) Interviewer Total Score at Week 12
The SCoRS is an interview-based measure of cognitive functioning that is developed to specifically assess aspects of cognitive functioning in participants with schizophrenia. The items assess the 7 cognitive domains of attention, memory, reasoning and problem solving, working memory, processing speed, language functions and social cognition. The SCoRS total score is the sum of the 20 items and varies from 20 to 80 with 20 being the best outcome and 80 being the worst. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Week 12, determined using a MMRM.
Time frame: Baseline and Week 12
Change From Baseline on the PANSS Total Score at Week 12
PANSS assesses the positive symptoms, negative symptoms and general psychopathology associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). The sum of the 30 items is defined as the PANSS total score and ranges from 30 to 210, where a higher score indicates greater severity. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Week 12, determined using a MMRM. A negative change from baseline indicates improvement.
Time frame: Baseline and Week 12
Change From Baseline on the PANSS Positive Symptom Factor Score (PSFS) at Week 12
PANSS assesses the positive symptoms, negative symptoms and general psychopathology associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Here, the PANSS PSFS subscale consists of 7 items which assess the positive symptoms with subscale score ranging from 7 to 49, where a higher score indicates greater severity. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Week 12, determined using a MMRM. A negative change from baseline indicates improvement.
Time frame: Baseline and Week 12
Luvadaxistat Plasma Concentrations
Blood samples were collected at pre-specified timepoints and plasma concentrations of luvadaxistat were measured. At Week 4, assessments were categorized as pre-dose or post-dose according to actual sampling time. Due to this, some participants may have had more than 1 record summarized for Week 4 pre-dose or Week 4 post-dose. Mean concentration on each visit was averaged from the observations over the time span of 24 hours post-dose or pre-dose.
Time frame: Pre-dose on Day 1 and Week 4 and post-dose on Weeks 4, 6, 8 and 12
| Milestone | Placebo | Luvadaxistat 50 Milligrams (mg) | Luvadaxistat 125 mg | Luvadaxistat 500 mg |
|---|---|---|---|---|
| Started | 87 | 58 | 56 | 55 |
| Completed | 76 | 53 | 52 | 47 |
| Not completed | 11 | 5 | 4 | 8 |
| Withdrew: Adverse event | 2 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 3 | 2 | 3 |
| Withdrew: Unsatisfactory therapeutic response | 1 | 0 | 0 | 0 |
| Withdrew: Noncompliance with study drug during the dbtp | 1 | 2 | 1 | 1 |
| Withdrew: Other | 2 | 0 | 0 | 3 |
PANSS assesses the positive symptoms, negative symptoms and general psychopathology associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Here, the PANSS NSFS subscale consists of 7 items which assess the negative symptoms with subscale score ranging from 7 to 49, where a higher score indicates greater severity. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as least squares (LS) mean change from baseline at Week 12, determined using a mixed model for repeated measures (MMRM). A negative change from baseline indicates improvement.
| scores on a scale | Placebo | Luvadaxistat 50 mg | Luvadaxistat 125 mg | Luvadaxistat 500 mg |
|---|---|---|---|---|
| Change From Baseline on the PANSS NSFS at Week 12 | -3.1 ± 0.44 | -3.3 ± 0.52 | -3.4 ± 0.51 | -2.5 ± 0.55 |
PANSS assesses the positive symptoms, negative symptoms and general psychopathology associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Here, the PANSS NSFS subscale consists of 7 items which assess the negative symptoms with subscale score ranging from 7 to 49, where a higher score indicates greater severity. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Weeks 4 and 8, determined using a MMRM. A negative change from baseline indicates improvement.
| scores on a scale | Placebo | Luvadaxistat 50 mg | Luvadaxistat 125 mg | Luvadaxistat 500 mg |
|---|---|---|---|---|
| Change at Week 4 | -1.7 ± 0.32 | -1.6 ± 0.39 | -1.8 ± 0.38 | -1.4 ± 0.40 |
| Change at Week 8 | -2.8 ± 0.39 | -2.2 ± 0.46 | -2.6 ± 0.45 | -2.3 ± 0.49 |
The BNSS is a 13-item instrument that measures 5 domains of negative symptoms: blunted affect, alogia, asociality, anhedonia and avolition. All items in the BNSS are rated on a 7-point (0-6) scale, with anchor points generally ranging from symptoms being absent (0) to severe (6). Here, the BNSS total score (12-item, excluding item 4) was calculated by summing the 12 individual items; total score range of 0 to 72, where a higher score indicates higher severity of negative symptoms. Participants required a BNSS total score ≥28 to be eligible for the study (excluding item 4). Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Week 12, determined using a MMRM. A negative change from baseline indicates improvement.
| scores on a scale | Placebo | Luvadaxistat 50 mg | Luvadaxistat 125 mg | Luvadaxistat 500 mg |
|---|---|---|---|---|
| Change From Baseline on the Brief Negative Symptom Scale (BNSS) Total Score (12-item) at Week 12 | -7.1 ± 1.04 | -8.9 ± 1.22 | -8.0 ± 1.22 | -6.0 ± 1.30 |
BACS is a cognition assessment battery and includes brief assessments of reasoning and problem solving, verbal fluency, attention, verbal memory, working memory and motor speed. The primary measure from each test is standardized by creating T-scores whereby the mean of the test session of a healthy person is set to 50 and the standard deviation set to 10. A composite T-score is calculated by averaging the 6 standardized primary measures. The composite T-score indicates how much higher or lower the participants cognition is compared to a healthy person. Lower T-scores are indicative of lower cognitive performance. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Day 12, determined using a MMRM.
| T-score | Placebo | Luvadaxistat 50 mg | Luvadaxistat 125 mg | Luvadaxistat 500 mg |
|---|---|---|---|---|
| Change From Baseline on the Brief Assessment of Cognition in Schizophrenia (BACS) Composite Score at Week 12 | 2.3 ± 0.83 | 4.6 ± 0.97 | 3.5 ± 0.96 | 2.3 ± 1.04 |
The CGI-SCH scale is an adapted version of the CGI scale that is designed to assess global illness status in participants with schizophrenia. CGI-SCH-S is a 7-point scale that requires the investigator to rate the severity of the participant's illness at the time of assessment. Here, CGI-SCH-S negative symptoms score assesses the severity of illness for negative symptoms on the following 7-point scale: 1. normal, not at all ill; 2. borderline mentally ill; 3. mildly ill; 4. moderately ill; 5. markedly ill; 6. severely ill; or 7. among the most extremely ill. Baseline was defined as the last observed value before the first dose of study treatment. The number of participants with each CGI-SCH-S negative symptoms score at baseline and at Week 12 is reported.
| Participants | Placebo | Luvadaxistat 50 mg | Luvadaxistat 125 mg | Luvadaxistat 500 mg |
|---|---|---|---|---|
| Baseline: Normal, not at all ill (1) | 0 | 0 | 0 | 0 |
| Baseline: Borderline mentally ill (2) | 0 | 0 | 1 | 0 |
| Baseline: Mildly ill (3) | 3 | 3 | 1 | 3 |
| Baseline: Moderately ill (4) | 36 | 28 | 25 | 22 |
| Baseline: Markedly ill (5) | 26 | 18 | 20 | 18 |
| Baseline: Severely ill (6) | 6 | 2 | 2 | 2 |
| Baseline: Among the most extremely ill (7) | 0 | 0 | 0 | 0 |
| Week 12: Normal, not at all ill (1) | 0 | 0 | 0 | 0 |
| Week 12: Borderline mentally ill (2) | 1 | 3 | 2 | 3 |
| Week 12: Mildly ill (3) | 13 | 14 | 12 | 11 |
| Week 12: Moderately ill (4) | 34 | 22 | 21 | 18 |
| Week 12: Markedly ill (5) | 20 | 11 | 13 | 12 |
| Week 12: Severely ill (6) | 3 | 1 | 1 | 1 |
| Week 12: Among the most extremely ill (7) | 0 | 0 | 0 | 0 |
The CGI-SCH-I assesses the participant's improvement (or worsening). CGI-SCH-I requires the investigator to assess the participant's condition relative to baseline on a 7-point scale. Here, CGI-SCH-I negative symptoms score assesses the improvement for negative symptoms on the following scale: very much improved; 2. much improved; 3. minimally improved; 4. no change; 5. minimally worse; 6. much worse; or 7. very much worse. Baseline was defined as the last observed value before the first dose of study treatment. The number of participants with each CGI-SCH-I negative symptoms score at Week 12 is reported.
| Participants | Placebo | Luvadaxistat 50 mg | Luvadaxistat 125 mg | Luvadaxistat 500 mg |
|---|---|---|---|---|
| 1 - Very much improved | 0 | 0 | 0 | 0 |
| 2 - Much improved | 10 | 13 | 12 | 5 |
| 3 - Minimally improved | 29 | 19 | 19 | 21 |
| 4 - No change | 32 | 19 | 16 | 18 |
| 5 - Minimally worse | 0 | 0 | 2 | 1 |
| 6 - Much worse | 0 | 0 | 0 | 0 |
| 7 - Very much worse | 0 | 0 | 0 | 0 |
The SCoRS is an interview-based measure of cognitive functioning that is developed to specifically assess aspects of cognitive functioning in participants with schizophrenia. The items assess the 7 cognitive domains of attention, memory, reasoning and problem solving, working memory, processing speed, language functions and social cognition. The SCoRS total score is the sum of the 20 items and varies from 20 to 80 with 20 being the best outcome and 80 being the worst. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Week 12, determined using a MMRM.
| scores on a scale | Placebo | Luvadaxistat 50 mg | Luvadaxistat 125 mg | Luvadaxistat 500 mg |
|---|---|---|---|---|
| Change From Baseline on the Schizophrenia Cognition Rating Scale (SCoRS) Interviewer Total Score at Week 12 | -1.6 ± 0.66 | -3.8 ± 0.77 | -2.3 ± 0.77 | -1.8 ± 0.83 |
PANSS assesses the positive symptoms, negative symptoms and general psychopathology associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). The sum of the 30 items is defined as the PANSS total score and ranges from 30 to 210, where a higher score indicates greater severity. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Week 12, determined using a MMRM. A negative change from baseline indicates improvement.
| scores on a scale | Placebo | Luvadaxistat 50 mg | Luvadaxistat 125 mg | Luvadaxistat 500 mg |
|---|---|---|---|---|
| Change From Baseline on the PANSS Total Score at Week 12 | -6.2 ± 1.00 | -7.2 ± 1.19 | -6.8 ± 1.18 | -5.0 ± 1.26 |
PANSS assesses the positive symptoms, negative symptoms and general psychopathology associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Here, the PANSS PSFS subscale consists of 7 items which assess the positive symptoms with subscale score ranging from 7 to 49, where a higher score indicates greater severity. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Week 12, determined using a MMRM. A negative change from baseline indicates improvement.
| scores on a scale | Placebo | Luvadaxistat 50 mg | Luvadaxistat 125 mg | Luvadaxistat 500 mg |
|---|---|---|---|---|
| Change From Baseline on the PANSS Positive Symptom Factor Score (PSFS) at Week 12 | -0.8 ± 0.33 | -1.3 ± 0.39 | -1.3 ± 0.39 | -0.6 ± 0.42 |
Blood samples were collected at pre-specified timepoints and plasma concentrations of luvadaxistat were measured. At Week 4, assessments were categorized as pre-dose or post-dose according to actual sampling time. Due to this, some participants may have had more than 1 record summarized for Week 4 pre-dose or Week 4 post-dose. Mean concentration on each visit was averaged from the observations over the time span of 24 hours post-dose or pre-dose.
| nanograms / milliliter | Luvadaxistat 50 mg | Luvadaxistat 125 mg | Luvadaxistat 500 mg |
|---|---|---|---|
| Day 1 - Pre-dose | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Week 4 - Pre-dose | 22.5 ± 44.44 | 106.5 ± 197.61 | 345.2 ± 653.08 |
| Week 4 - Post-dose | 79.0 ± 115.75 | 229.8 ± 368.27 | 480.2 ± 717.15 |
| Week 6 | 83.60 ± 123.38 | 183.60 ± 257.44 | 409.3 ± 502.26 |
| Week 8 | 109.3 ± 144.76 | 202.1 ± 294.60 | 366.80 ± 473.74 |
| Week 12 | 61.50 ± 113.94 | 185.62 ± 258.73 | 356.0 ± 461.42 |
Collected over 12-week double-blind treatment period and up to 30 days follow-up: Day 1 up to Day 114.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/87 (0%) | 4/87 (4.6%) | 4/87 (4.6%) |
| Luvadaxistat 50 mg | 0/58 (0%) | 0/58 (0%) | 0/58 (0%) |
| Luvadaxistat 125 mg | 0/56 (0%) | 1/56 (1.8%) | 5/56 (8.9%) |
| Luvadaxistat 500 mg | 0/55 (0%) | 0/55 (0%) | 2/55 (3.6%) |
| Event | Placebo | Luvadaxistat 50 mg | Luvadaxistat 125 mg | Luvadaxistat 500 mg |
|---|---|---|---|---|
| SchizophreniaPsychiatric disorders | 0/87 | 0/58 | 1/56 | 0/55 |
| Psychotic disorderPsychiatric disorders | 1/87 | 0/58 | 0/56 | 0/55 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 1/87 | 0/58 | 0/56 | 0/55 |
| COVID-19Infections and infestations | 1/87 | 0/58 | 0/56 | 0/55 |
| Tooth abscessInfections and infestations | 1/87 | 0/58 | 0/56 | 0/55 |
| Event | Placebo | Luvadaxistat 50 mg | Luvadaxistat 125 mg | Luvadaxistat 500 mg |
|---|---|---|---|---|
| HeadacheNervous system disorders | 4/87 | 0/58 | 5/56 | 2/55 |
The Full Analysis Set (FAS) will included all participants who were randomized and received at least 1 dose of the study drug during the Double-Blind Treatment Period.
| Age, Categorical(Participants) | Placebo | Luvadaxistat 50 mg | Luvadaxistat 125 mg | Luvadaxistat 500 mg | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 87 | 58 | 56 | 55 | 256 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Placebo | Luvadaxistat 50 mg | Luvadaxistat 125 mg | Luvadaxistat 500 mg | Total |
|---|---|---|---|---|---|
| Female | 24 | 20 | 22 | 22 | 88 |
| Male | 63 | 38 | 34 | 33 | 168 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Luvadaxistat 50 mg | Luvadaxistat 125 mg | Luvadaxistat 500 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 2 | 1 | 8 |
| Not Hispanic or Latino | 19 | 12 | 18 | 8 | 57 |
| Unknown or Not Reported | 65 | 44 | 36 | 46 | 191 |
| Race (NIH/OMB)(Participants) | Placebo | Luvadaxistat 50 mg | Luvadaxistat 125 mg | Luvadaxistat 500 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 1 | 0 | 3 |
| Asian | 2 | 0 | 3 | 0 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 5 | 5 |
| Black or African American | 10 | 9 | 9 | 0 | 28 |
| White | 70 | 46 | 42 | 50 | 208 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 3 | 1 | 0 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2018 to primary completion in Dec 2020, 35 months.
Results were first posted in Feb 2024, 3 years 1 month after primary completion. A results delay was requested in Dec 2021.
Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 35 months is above that.
Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Luvadaxistat